Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Protein study seeks to unlock muscle loss mystery in heart and lung patients

NCT ID NCT02770092

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how people with chronic heart failure or COPD process protein from meals. Researchers measured muscle building, body composition, and gut function in 90 adults aged 45 and older. The goal was to understand why muscle loss happens and how to design better diets for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Feb 2016

Finished

May 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria CHF subjects: * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lie in supine or elevated position for 8 hours * Diagnosis of CHF; under regular care by cardiologist * Reduced ejection fraction (\<45%) assessed in the past 2 years * NYHA class II-IV * Clinically stable condition; no hospitalization 4 weeks preceding first study day * Willingness and ability to comply with the protocol Inclusion criteria COPD subjects: * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lie in supine or elevated position for 8 hours * Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: FEV1 \< 70% of reference FEV1 * Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 \> 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day * Shortness of breath on exertion * Willingness and ability to comply with the protocol Inclusion criteria healthy subjects: * Healthy male or female according to the investigator's or appointed staff's judgment * Ability to walk, sit down and stand up independently * Age 45 years or older (older control group) * Age between 20-30 years old (young group) * Ability to lay in supine or elevated position for 8 hours * No diagnosis of CHF or COPD * Willingness and ability to comply with the protocol Exclusion Criteria all subjects: * Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (healthy subjects only) * Established diagnosis of malignancy * History of untreated metabolic diseases including hepatic or renal disorder * Presence of acute illness or metabolically unstable chronic illness * Presence of fever within the last 3 days * Body mass index \>40 kg/m2 (healthy subjects only) * Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient * Use of protein or amino acid containing nutritional supplements within 5 days of first study day * Current Use of long-term oral corticosteroids (CHF only) * Use of short course of oral corticosteroids within 4 weeks preceding first study day * Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * (Possible) pregnancy * Already enrolled in another clinical trial and that clinical trial interferes with participating in this study When during the period from enrollment to the test day any condition causing the subject to not meet inclusion criteria or to meet exclusion criteria, the subject will be excluded from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congestive heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas A&M University-CTRAL

    College Station, Texas, 77843, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.